Skip to content

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06023368
Enrollment
0
Registered
2023-09-05
Start date
2023-12-23
Completion date
2024-06-20
Last updated
2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cancer

Keywords

Port access pain, pediatric, oncology

Brief summary

The goal of this clinical trial is to compare a sterile vapocoolant spray to EMLA cream in children with access ports. Participants will receive either the spray or cream prior to port access and rate pain on a scale. Researchers will compare spray vs cream to see if the spray is as effective as the cream in reducing pain associated with port puncture.

Interventions

Spray applied around port prior to access

cream applied around the port prior to access

Sponsors

Bimeco Group
CollaboratorUNKNOWN
Marianne Hutti
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* English-speaking * Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy * EMLA cream has (standard of care) or has not (vapocoolant) been applied to the port site prior to the appointment * Previous allergic reaction or skin irritation due to EMLA * Quick access to the child's port is needed for drawing blood, or giving treatments, blood products, or drugs such as chemotherapy

Exclusion criteria

* Child has a legal guardian or non-parent family member as the only adult with them for the visit. * Children less than 4 years of age * Children with altered mental status * History of traumatic brain injury, developmental delay or autism * Child is nonverbal * Present appointment is for drawing blood, receiving intravenous antibiotics, blood products, or chemotherapy, and child and parents prefer to wait for EMLA cream to take effect.

Design outcomes

Primary

MeasureTime frameDescription
Port Access PainWithin 5 minutes of port accessPain will be measured by The Faces Pain Scale - Revised (FPS-R). FPS-R is a self-report measure of pain intensity developed for children. It was adapted from the Faces Pain Scale to make it possible to score the sensation of pain on the widely accepted 0-to-10 metric. Higher scores mean increased pain.
Clinic Wait TimeDay of visit, up to 8 hoursWait time will be measured in minutes from check in to check out
Duration of VisitDay of visit, up to 8 hoursTotal length of overall appointment time measured in minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026